Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with relapsed/refractory non-Hodgkin lymphoma.

被引：0

作者：

Zhang, Yajing ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

基金：

中国国家自然科学基金;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3034

引用

页数：1

共 50 条

[41] Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Hernandez, Genevive
Huw, Ling-Yuh
Belousov, Anton
Wilson, Deanna
Koeppen, Hartmut
McCord, Ron
Peng, Kun
Bartlett, Nancy L.
Budde, Lihua E.
Assouline, Sarit
Nastoupil, Loretta J.
Yoon, Dok Hyun
Matasar, Matthew J.
Bender, Brendan
Kwan, Antonia
Li, Chi-Chung
O'Hear, Carol
Yin, Shen
Wei, Michael C.
Adamkewicz, Joanne I.
BLOOD, 2019, 134
[42] Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Shadman, Mazyar
Yeung, Cecilia
Redman, Mary W.
Lee, Sang Yun
Lee, Dong Hoon
Ramachandran, Ajeetha
Ra, Susan
Marzbani, Edmond A.
Graf, Solomon A.
Warren, Edus H.
Gopal, Ajay K.
Chapuis, Aude G.
Bar, Merav
Green, Damian J.
Gauthier, Jordan
Cassaday, Ryan D.
Kiem, Hans-Peter
Turtle, Cameron J.
Maloney, David G.
Till, Brian G.
BLOOD, 2020, 136
[43] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
Maus, Marcela V.
LANCET, 2021, 398 (10299): : 466 - 467
[44] CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
Onea, Alexandra S.
Jazirehi, Ali R.
AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (02): : 403 - 424
[45] CD28-COSTIMULATED CD19 CAR T CELLS FOR PEDIATRIC RELAPSED AND REFRACTORY MATURE B-CELL LYMPHOMA
Jacoby, Elad
Adam, Etai
Abramovich, Alon
Shapira, Adi
Hutt, Daphna
Itzhaki, Orit
Bielorai, Bella
Toren, Amos
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 563 - 564
[46] Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Liu, Wei Ping
Jiang, Bo
Shuang, Yue Rong
Zhao, Xing
Zhong, Xuan Fan
Tan, Ying
Yu, Guo Jian
Xue, Sheng Jie
Shen, Wu Zhong
Tu, Gui Yun
Yang, Zheng
Chen, Han Yang
Xu, Jason
Liu, Shui
Yan, Xiao Qiang Qiang
Zhu, Jun
Song, Yu Qin
BLOOD, 2023, 142
[47] Early response data for pediatric patients with Non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells
Rivers, Julie
Annesley, Colleen
Summers, Corinne
Finney, Olivia
Pulsipher, Michael
Wayne, Alan
Park, Julie
Jensen, Michael
Gardner, Rebecca
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 23 - 24
[48] Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells
Rivers, Julie
Annesley, Colleen
Summers, Corinne
Finney, Olivia
Pulsipher, Michael A.
Wayne, Alan S.
Park, Julie R.
Jensen, Michael C.
Gardner, Rebecca
BLOOD, 2018, 132
[49] Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma
Stadel, Ryan
Liu, Ruifu
Landesman, Yosef
Wald, David
Vasanna, Smitha Hosahalli
de Lima, Marcos J. G.
BLOOD, 2022, 140 : 7413 - 7414
[50] Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Maude, Shannon L.
Barrett, David M.
Ambrose, David E.
Rheingold, Susan R.
Aplenc, Richard
Teachey, David T.
Callahan, Colleen
Barker, Christine S.
Mudambi, Maya
Shaw, Pamela A.
Brogdon, Jennifer
Young, Regina M.
Scholler, John
Loew, Andreas
Marcucci, Katherine T.
Finklestein, Jeffrey
Kulikovskaya, Irina
Nazimuddin, Farzana
Zheng, Zhaohui
Levine, Bruce L.
Porter, David L.
Lacey, Simon F.
Melenhorst, Jan J.
June, Carl H.
Grupp, Stephan A.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →